The Effect of Sitagliptin in Type 2 Diabetes Mellitus With Inadequate Glycemic Control (MK0431-118)

Phase 4TerminatedNCT00832624

Merck Sharp & Dohme LLC10 enrolled

Overview

to assess the effect of treatment with Sitagliptin (MK0431) on HbA1c (Hemoglobin A1c) and the safety and tolerability of Sitagliptin.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Diabetes Mellitus Non-insulin-dependent

Interventions

sitagliptinDRUG

Sitagliptin, 100 mg, 1 Tablet, once a day, for 18 weeks

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients Who Are 18 Years Of Age With Type 2 Diabetes Mellitus Who Are Either: * Not On Antihyperglycemic (AHa) Medication (Off For At Least 2 Months) * Or On A Single AHa

Outcomes

Primary Outcomes

Change From Baseline in HbA1c (Hemoglobin A1c) at Week 18

Glycosylated hemoglobin (HbA1c) was to be measured as the percentage of hemoglobin that has glucose bound to it; however, the study was terminated early therefore no laboratory tests were performed, and no outcome data was collected.

Time frame: Baseline and Week 18

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.